These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36579526)

  • 1. NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series.
    Iannantuono GM; Riondino S; Sganga S; Rosenfeld R; Guerriero S; Carlucci M; Capotondi B; Torino F; Roselli M
    J Pers Med; 2022 Nov; 12(11):. PubMed ID: 36579526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs.
    Han SY
    Pharmaceuticals (Basel); 2021 Jun; 14(7):. PubMed ID: 34209967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future Directions.
    Gouda MA; Thein KZ; Hong DS
    Cancers (Basel); 2024 Oct; 16(19):. PubMed ID: 39410015
    [No Abstract]   [Full Text] [Related]  

  • 4. NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance.
    Liu F; Wei Y; Zhang H; Jiang J; Zhang P; Chu Q
    Front Oncol; 2022; 12():864666. PubMed ID: 35372074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China.
    Xu C; Si L; Wang W; Li Z; Song Z; Wang Q; Liu A; Yu J; Fang W; Zhong W; Wang Z; Zhang Y; Liu J; Zhang S; Cai X; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Chen Y; Yuan J; Wang F; Jiang Z; Lin G; Pu X; Lin R; Liu W; Rao C; Lv D; Yu Z; Lei L; Li X; Tang C; Zhou C; Zhang J; Xue J; Guo H; Chu Q; Meng R; Wu J; Zhang R; Hu X; Zhou J; Zhu Z; Li Y; Qiu H; Xia F; Lu Y; Chen X; Ge R; Dai E; Han Y; Pan W; Luo J; Jia H; Dong X; Pang F; Wang K; Wang L; Zhu Y; Xie Y; Lin X; Cai J; Wei J; Lan F; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Huang J; Zhang Y; Sun P; Wang H; Ye M; Wang D; Wang Z; Wan B; Lv D; Wei Q; Kang J; Zhang J; Zhang C; Yu G; Ou J; Shi L; Li Z; Liu Z; Liu J; Yang N; Wu L; Wang H; Jin G; Yang L; Wang G; Fang M; Fang Y; Li Y; Wang X; Zhang Y; Ma S; Wang B; Zhang X; Song Y; Lu Y
    Thorac Cancer; 2022 Nov; 13(21):3084-3097. PubMed ID: 36127731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How selecting best therapy for metastatic
    Ekman S
    Transl Lung Cancer Res; 2020 Dec; 9(6):2535-2544. PubMed ID: 33489816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults.
    Bebb DG; Banerji S; Blais N; Desmeules P; Gill S; Grin A; Feilotter H; Hansen AR; Hyrcza M; Krzyzanowska M; Melosky B; Noujaim J; Purgina B; Ruether D; Simmons CE; Soulieres D; Torlakovic EE; Tsao MS
    Curr Oncol; 2021 Jan; 28(1):523-548. PubMed ID: 33467570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
    Laetsch TW; Hong DS
    Clin Cancer Res; 2021 Sep; 27(18):4974-4982. PubMed ID: 33893159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer.
    Koehler VF; Achterfeld J; Sandner N; Koch C; Wiegmann JP; Ivanyi P; Käsmann L; Pusch R; Wolf D; Chirica M; Knösel T; Demes MC; Kumbrink J; Vogl TJ; Meyer G; Spitzweg C; Bojunga J; Kroiss M
    J Cancer Res Clin Oncol; 2023 Nov; 149(15):14035-14043. PubMed ID: 37548775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice.
    Vingiani A; Lorenzini D; Conca E; Volpi CC; Trupia DV; Gloghini A; Perrone F; Tamborini E; Dagrada GP; Agnelli L; Capone I; Busico A; Pruneri G
    Cancer Biomark; 2023; 38(3):301-309. PubMed ID: 37545217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.
    Kummar S; Lassen UN
    Target Oncol; 2018 Oct; 13(5):545-556. PubMed ID: 30276762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnosis and therapy of tumors with NTRK gene fusion].
    Stenzinger A; van Tilburg CM; Tabatabai G; Länger F; Graf N; Griesinger F; Heukamp LC; Hummel M; Klingebiel T; Hettmer S; Vokuhl C; Merkelbach-Bruse S; Overkamp F; Reichardt P; Scheer M; Weichert W; Westphalen CB; Bokemeyer C; Ivanyi P; Loges S; Schirmacher P; Wörmann B; Bielack S; Seufferlein TTW
    Pathologe; 2021 Feb; 42(1):103-115. PubMed ID: 33258061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.
    Harada G; Drilon A
    Cancer Genet; 2022 Jun; 264-265():33-39. PubMed ID: 35334340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy.
    Haratake N; Seto T
    Clin Lung Cancer; 2021 Jan; 22(1):1-5. PubMed ID: 33272813
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Siozopoulou V; Smits E; De Winne K; Marcq E; Pauwels P
    Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33803146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies.
    Pollack M; Keating K; Wissinger E; Jackson L; Sarnes E; Cuffel B
    Curr Med Res Opin; 2021 Jan; 37(1):59-70. PubMed ID: 33148054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
    Filippi R; Depetris I; Satolli MA
    Expert Opin Pharmacother; 2021 Apr; 22(6):677-684. PubMed ID: 33576301
    [No Abstract]   [Full Text] [Related]  

  • 20. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
    Hsiao SJ; Zehir A; Sireci AN; Aisner DL
    J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.